SGLT2 inhibitors and GLP1-receptor agonists reduce CHD risk in diabetes patients: Study

Italy: Both SGLT2 inhibitors and GLP1-receptor agonists reduce the 10-year risk for cardiovascular disease in type 2 diabetes (T2D) patients without baseline CHD, reveals data from real-world study. After 1 year of treatment, a greater percentage of patients discontinued SGLT2i versus GLP1 RA.

The findings of the study are published in the journal Diabetes Research and Clinical Practice.

Ernesto Maddaloni, Sapienza University of Rome, Rome, Italy, and colleagues aimed to evaluate the effect of glucagon-like peptide1 receptor-agonist (GLP1 RA) and sodium-glucose co-transporter2 inhibitor (SGLT2i) on the risk of coronary heart disease (CHD) in type 2 diabetes (T2D) in primary cardiovascular prevention, in this real-world study. 

For the purpose, the researchers prospectively collected data from 312 patients with T2D, without CHD history, starting treatment with GLP1 RA (n = 174) or SGLT2i (n = 138). UKPDS-RE score was used for estimating 10-years risk for CHD before and 6, 12 and 24 months after prescription. 

"This real-world study shows that both GLP1 RA and SGLT2i reduce the 10-year risk for cardiovascular disease in patients with T2D in primary cardiovascular prevention," wrote the authors. 

"Further, the median CHD risk reduction was higher in the SGLT2i compared to the GLP1 RA group at 6 and 12 months." 

Reference:

The study titled, "Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study," is published in the journal Diabetes Research and Clinical Practice.

DOI: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(21)00034-6/fulltext